Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial

              Author:Steinman, Lawrence   Selmaj, Krzysztof   Comi, Giancarlo   Bar-Or, Amit   Arnold, Douglas   Hartung, Hans-Peter   Montalban, Xavier   Havrdova, Eva   Sheffield, James   Cheng, Chun-Yen   Reardon, Jennifer   Riolo, Jon   Deboer, Erik   Kappos, Ludwig   Cohen, Jeffrey   Cree, Bruce   

              Session Name:P2: Multiple Sclerosis: Clinical Practice and Decision Making 2  

              Topic:Multiple Sclerosis  

              Program Number:P2.007  

              Author Institution:Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Center for Neurology, Lódz, Poland, and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Lodz, Poland  Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montreal, QC, Canada  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic, Prague, Czech Republic  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

              Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials

              Author:Filippi, Massimo   Riolo, Jon   Cohen, Jeffrey   Hartung, Hans-Peter   Montalban, Xavier   Meuth, Sven   Freeman, Leorah   Chitnis, Tanuja   Granziera, Cristina   Deboer, Erik   Cheng, Chun-Yen   Reardon, Jennifer   Pachai, Chahin   Sheffield, James   Cree, Bruce   Kappos, Ludwig   

              Session Name:P6: Multiple Sclerosis: Clinical Assessments Including Digital Tools and Outcome Measures 2  

              Topic:Multiple Sclerosis  

              Program Number:P6.014  

              Author Institution:Neuroimaging Research Unit, Division of Neuroscience, Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy, Milan, Italy  Bristol Myers Squibb, Princeton, New Jersey, USA, Princeton, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany, Duesseldorf, Germany  Dell Medical School, The University of Texas at Austin, Austin, Texas, USA, Austin, TX  Brigham and Women’s Hospital, and Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, Boston, MA  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland  Department of Neurology, University Hospital Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Bristol Myers Squibb, Princeton, New Jersey, USA, New York, NY  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA , San Francisco, CA  

              Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis

              Author:Selmaj, Krzysztof   Ziemssen, Tjalf   Comi, Giancarlo   Hartung, Hans-Peter   Reardon, Jennifer   Thorpe, Andrew   Riolo, Jon   Cheng, Chun-Yen   Sheffield, James   Krakovich, Anthony   Vermersch, Patrick   Cree, Bruce   

              Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

              Topic:Multiple Sclerosis  

              Program Number:P10.012  

              Author Institution:Center for Neurology, Lódz, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Lodz, Poland  Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Dresden, Germany, Dresden, Germany  Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy, Milan, Italy  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacky University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Univ. Lille, Inserm UMR 1172, CHU Lille, FHU Precise, Lille, France, Lille, France  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

              Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis

              Author:Hartung, Hans-Peter   Steinman, Lawrence   Bar-Or, Amit   Sheffield, James   Harris, Sarah   Riolo, Jon   Cheng, Chun-Yen   Reardon, Jennifer   Thorpe, Andrew   Cree, Bruce   

              Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

              Topic:Multiple Sclerosis  

              Program Number:P10.013  

              Author Institution:Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA